Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADS Alliance Data Systems		$63.61	$53.30 ▼ $128.16	$2.84B	2.1	999,503 shs	13,896 shs
ADYEY Adyen	$15.14 -0.4%	$15.97	$6.55 ▼ $18.69	$46.98B	2.59	879,337 shs	473,903 shs
BUD Anheuser-Busch InBev SA/NV	$57.90 +0.9%	$61.24	$51.66 ▼ $66.56	$100.58B	1.13	2.09 million shs	1.46 million shs
VOR Vor Biopharma	$1.68 -2.9%	$2.07	$1.62 ▼ $5.70	$114.61M	-0.36	296,718 shs	152,547 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADS Alliance Data Systems	0.00%	0.00%	0.00%	0.00%	-2.03%
ADYEY Adyen	+0.66%	-2.25%	-2.50%	+21.50%	-5.59%
BUD Anheuser-Busch InBev SA/NV	+0.39%	-3.71%	-4.51%	-8.53%	-10.89%
VOR Vor Biopharma	+1.17%	-12.18%	-9.90%	-29.96%	-60.32%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADS Alliance Data Systems	0.733 of 5 stars	0.0	0.0	2.5	1.7	0.0	1.7	1.9
ADYEY Adyen	1.4391 of 5 stars	0.0	5.0	0.0	0.0	2.8	0.0	1.9
BUD Anheuser-Busch InBev SA/NV	2.5833 of 5 stars	2.3	3.0	2.5	0.0	2.3	0.0	2.5
VOR Vor Biopharma	3.0381 of 5 stars	4.5	0.0	0.0	0.0	1.9	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADS Alliance Data Systems	N/A	N/A	N/A	N/A
ADYEY Adyen	2.33	Hold	N/A	N/A
BUD Anheuser-Busch InBev SA/NV	2.67	Moderate Buy	$71.70	23.83% Upside
VOR Vor Biopharma	3.00	Buy	$13.50	703.57% Upside

Current Analyst Ratings

Latest VOR, ADS, AV1, ADYEY, and BUD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/22/2024	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$12.00
3/21/2024	VOR Vor Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/21/2024	VOR Vor Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$17.00 ➝ $15.00
3/21/2024	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
3/21/2024	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.50
3/5/2024	BUD Anheuser-Busch InBev SA/NV	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $65.00
1/18/2024	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADS Alliance Data Systems	$3.27B	0.00	N/A	2.77	$41.90 per share	0.00
ADYEY Adyen	$2.02B	23.30	N/A	N/A	N/A	∞
BUD Anheuser-Busch InBev SA/NV	$59.38B	1.69	$6.75 per share	8.58	$53.35 per share	1.09
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADS Alliance Data Systems	$801M	$16.02	3.55	0.00	N/A	19.75%	43.42%	4.07%	N/A
ADYEY Adyen	$755.73M	N/A	0.00	42.06	2.15	N/A	N/A	N/A	N/A
BUD Anheuser-Busch InBev SA/NV	$5.34B	$2.65	21.85	14.85	1.73	8.99%	13.57%	5.65%	5/8/2024 (Confirmed)
VOR Vor Biopharma	N/A	-$1.76	N/A	N/A	N/A	N/A	N/A	N/A	5/9/2024 (Estimated)

Latest VOR, ADS, AV1, ADYEY, and BUD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2024	N/A	BUD Anheuser-Busch InBev SA/NV	$0.71	N/A	-$0.71	N/A	N/A	N/A
3/20/2024	Q4 2023	VOR Vor Biopharma	-$0.49	-$0.39	+$0.10	-$0.39	N/A	N/A
2/28/2024	12/31/2023	BUD Anheuser-Busch InBev SA/NV	$0.76	$0.82	+$0.06	$0.70	$15.34 billion	$14.47 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADS Alliance Data Systems	$0.84	N/A	N/A	5.24%	N/A
ADYEY Adyen	N/A	N/A	N/A	N/A	N/A
BUD Anheuser-Busch InBev SA/NV	$0.61	1.05%	+13.24%	23.02%	1 Years
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Latest VOR, ADS, AV1, ADYEY, and BUD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/17/2024	BUD Anheuser-Busch InBev SA/NV	annual	$0.8722	1.1%	5/3/2024	5/6/2024	6/7/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADS Alliance Data Systems	0.95	1.13	1.13
ADYEY Adyen	N/A	N/A	N/A
BUD Anheuser-Busch InBev SA/NV	0.80	0.63	0.48
VOR Vor Biopharma	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ADS Alliance Data Systems	99.97%
ADYEY Adyen	0.08%
BUD Anheuser-Busch InBev SA/NV	5.53%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ADS Alliance Data Systems	0.19%
ADYEY Adyen	N/A
BUD Anheuser-Busch InBev SA/NV	4.50%
VOR Vor Biopharma	12.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADS Alliance Data Systems	6,000	49.95 million	49.85 million	Optionable
ADYEY Adyen	4,196	3.10 billion	N/A	Not Optionable
BUD Anheuser-Busch InBev SA/NV	155,000	1.74 billion	1.66 billion	Optionable
VOR Vor Biopharma	168	68.22 million	59.76 million	Not Optionable

VOR, ADS, AV1, ADYEY, and BUD Headlines

Source	Headline
	Vor Biopharma (NYSE:VOR) Trading Down 5.3% americanbankingnews.com - April 16 at 1:52 AM
	Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential markets.businessinsider.com - April 13 at 12:43 AM
	Seven diseases CRISPR technology could cure labiotech.eu - April 4 at 7:22 PM
	Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock zacks.com - April 4 at 9:36 AM
	Vor Bio to Participate in Upcoming Investor Conferences globenewswire.com - April 1 at 8:00 AM
	Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation finance.yahoo.com - March 29 at 7:12 AM
	The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness investorplace.com - March 28 at 2:28 PM
	Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR) markets.businessinsider.com - March 26 at 1:44 AM
	Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR) markets.businessinsider.com - March 22 at 3:59 PM
	Vor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP Securities marketbeat.com - March 22 at 2:11 PM
	Vor Biopharma Inc. Expected to Post Q1 2025 Earnings of ($0.24) Per Share (NYSE:VOR) marketbeat.com - March 22 at 8:35 AM
	Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update finanznachrichten.de - March 22 at 5:21 AM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE) markets.businessinsider.com - March 21 at 7:20 PM
	Vor Biopharma (NYSE:VOR) Price Target Cut to $12.00 by Analysts at Stifel Nicolaus marketbeat.com - March 21 at 10:56 AM
	Oppenheimer Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR) marketbeat.com - March 21 at 9:38 AM
	Vor Biopharma: Q4 Earnings Insights benzinga.com - March 20 at 9:49 PM
	Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update finance.yahoo.com - March 20 at 4:49 PM
	Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update globenewswire.com - March 20 at 4:05 PM
	Vor Biopharma (VOR) to Release Quarterly Earnings on Thursday marketbeat.com - March 20 at 7:46 AM
	Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial msn.com - March 19 at 5:15 PM
	VOR Apr 2024 5.000 call finance.yahoo.com - March 16 at 11:47 PM
	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - March 5 at 4:01 PM
	Vor Bio to Participate in Upcoming Investor Conferences globenewswire.com - March 4 at 8:00 AM
	Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company finance.yahoo.com - February 17 at 9:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Analysts are Bullish on These 4 Oversold Large Cap Stocks
April 1, 2024 11:37 AM
View Analysts are Bullish on These 4 Oversold Large Cap Stocks
Low Interest Rates Can Help These Commercial Banks Rally Higher
April 2, 2024 11:38 AM
View Low Interest Rates Can Help These Commercial Banks Rally Higher
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
April 12, 2024 7:32 AM
View 2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money
PDD Holdings Stock Can Have Another Double-Digit Rally This Week
March 20, 2024 8:00 AM
View PDD Holdings Stock Can Have Another Double-Digit Rally This Week

All Headlines

Company Descriptions

Alliance Data Systems

NYSE:ADS

Alliance Data Systems Corp. engages in the provision of data-driven and transaction-based marketing, customer loyalty and payment solutions. Its products and services include credit cards, loan financing, processing, and servicing, marketing, data and analytics, and digital offerings. The company was founded in 1996 and is headquartered in Columbus, Ohio.

Adyen

OTCMKTS:ADYEY

Adyen N.V. operates a payments platform in Europe, the Middle East, Africa, North America, the Asia Pacific, Latin America. The company's platform integrates payments stack that include gateway, risk management, processing, issuing, acquiring, and settlement services. It offers a back-end infrastructure for authorizing. It serves digital, mobility, platforms and marketplace, retail, food and beverages, subscription, and hospital businesses. Adyen N.V. was incorporated in 2006 and is headquartered in Amsterdam, the Netherlands.

Anheuser-Busch InBev SA/NV

NYSE:BUD

Anheuser-Busch InBev SA/NV produces, distributes, exports, markets, and sells beer and beverages. It offers a portfolio of approximately 500 beer brands, which primarily include Budweiser, Corona, and Stella Artois; Beck's, Hoegaarden, Leffe, and Michelob Ultra; and Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol brands. The company operates in North America, Middle America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1366 and is headquartered in Leuven, Belgium.

Vor Biopharma

NYSE:VOR

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial